Market Overview
The worldwide duodenal cancer market is anticipated to develop gradually over the forecast period. The global duodenal cancer market is estimated to record a CAGR of 3.2% over the forecast period of 2018–2023.
It is a rare kind of cancer that develops in the uppermost part of the small intestine. As the cancer cells start generating in the duodenum, it develops tumors. The tumors block food from passing through the digestive tract. At this point, the body or the small intestine is unable to extract the essential vitamins. The patient experiences a number of symptoms.
Symptoms can be ambiguous, which makes early diagnosis difficult. Duodenum plays a significant role in the digestive system. Bile and chemical secretions are passed through duodenum which helps the food to break down. Duodenal cancer disrupts the digestive process and prevents the body from absorbing essential minerals. Several diagnoses have managed to detect it at an early stage. Tests that capture detailed images of the GI tract, such as a CT scan or MRI, tests such as endoscopy, that examines the inner surface of the GI tract with the help of a flexible pipe with an attached small camera or the technique widely known as biopsy where a part of tissue is eliminated for analysis, could help the patient with the early detection of the disease.
Rising prevalence of chronic ailments, increasing instances of rare cancers, increasing geriatric population, and technological advancements are projected to stimulate the market growth. In January 2018, for instance, GE Healthcare entered into a long-term partnership with Roche Diagnostics to co-create and promote digital medical decision support services. With this, the firms will primarily focus on solutions that improve and accelerate personalized treatment options for critical care patients.
Furthermore, increased healthcare investment is likely to influence the worldwide duodenal cancer market size. However, strict administrative regulations for product approval and expensive treatments are major factors undermining the market potential.
Market Segmentation
The worldwide duodenal cancer market has been segmented based on treatment, diagnosis, and type.
Based on treatment, the market has been segmented into chemotherapy, radiotherapy, and surgery.
Based on diagnosis, the market has been segmented into capsule endoscopy, colonoscopy or endoscopy, MRI scan, CT scan, barium X-ray, and other tests.
Based on type, the global duodenal market has been segmented into sarcoma, adenocarcinoma, lymphoma, and neuroendocrine (carcinoid) tumors.
Regional Analysis
The Americas lead the worldwide duodenal cancer market owing to factors such as high healthcare expenditure, growing incidences of chronic & rare ailments, and access to well-established healthcare system. The American Society of Clinical Oncology (ASCO) recorded in January 2018 that 60% of the population had been diagnosed with duodenal cancer at the distant or initial phase. Europe holds the second-largest market share on account of the healthcare supports provided by the government coupled with the occurrences of several chronic ailments. The Asia-Pacific market is likely to be driven by factors such as surge in disposable income, government funding for healthcare units and growing prevalence of chronic diseases. MEA accounts for the smallest share of the global duodenal cancer market. The market growth in this region can be attributed to the improving healthcare set-up and increasing investment in the healthcare sector.
Key Players
The key players in the worldwide duodenal cancer market includes Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, AbbVie, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Thermo Fisher Scientific, Bayer AG, Boehringer Ingelheim International GmbH, Ipsen Biopharmaceuticals Inc., Abbott, G E Healthcare, AstraZeneca, Agilent Technologies Inc., Dickinson & Company, and Becton.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment